C21 · Pharmaceuticals · Global
Common new active substance approvals across major regulatory authorities (multi-year total)
Global: 52 in 2021–2025, +40.5% on 2016–2020.
- 52 Latest · Global · 2021–2025
- +40.5% vs 2016–2020
- Irregular Release cadence
- 2 Records · 1 region · 2016–2025
Verified 27 Sep 2026 · 1 publisher
Over time
Global over time. Forecasts are dashed with hollow markers; the underlying values are one click away under the chart.
Common new active substance approvals across major regulatory authorities (multi-year total)
Global, 2016–2020 to 2021–2025
Every record
2 records · 1 region · 2016–2025. Each period links to its record: the value, the quote it was read from, and the document.
Download this data
Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: CIRS. Licence: CC BY 4.0.
Embed this chart
Free to embed anywhere, including commercially. The attribution bar is part of the chart.
Use and publication rights
- View, cite and link: free
Quote any number, cite this page or a single record, and link to it anywhere.
- Copy, chart and republish: free with attribution
The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (CIRS); the chart files already carry that line.
- The source documents: the publisher's terms
Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.
How this measure is built
- Definition
- Total count of new active substances approved across all designated major regulatory authorities during the period.
- Measure
- One slice of Drug approvals ( basis: cumulative, counting rule: common across authorities, form: count, segment: new active substance ) . Total number of therapeutic drugs granted regulatory marketing approval. Region and period are columns on every record, not slices.
- Limitations
- Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
- Verification
- Each value, unit, period and place was checked against its quote before publication. See the methodology and the corrections process.
Sources · 1 document
| Document | Publisher | Published | Data points |
|---|---|---|---|
| New Drug Approvals by Six Major Authorities 2016-2025 | CIRS | — | 2 |
Other slices of drug approvals
- First-in-class drug approvals 9 first in class
- New active substance approvals 6 new active substance
- Innovative drug approvals 5 innovative
- Novel drug approvals 3 novel
- Pediatric medicine approvals 3 pediatric
- Rare disease medicine approvals 3 rare disease
- Approved innovative drugs designated as breakthrough therapies 2 breakthrough therapy
- Domestic first-in-class drug approvals 2 domestic · first in class
- Domestic innovative biological product approvals 2 domestic · innovative biologic
- Domestic innovative chemical drug approvals 2 domestic · innovative chemical
- Domestic innovative drug approvals (half year) 2 domestic · innovative
- Domestic share of approved innovative biological products 2 domestic · innovative biologic
Frequently asked questions
What is the latest common new active substance approvals across major regulatory authorities (multi-year total)?
Global: 52 in 2021–2025, +40.5% on 2016–2020.
Where does this data come from?
From 1 document published by CIRS. Every figure on this page links to its record, which quotes the sentence or table row the number was read from.
How often is it updated?
Irregularly: the publishers behind this measure do not release it on a fixed schedule. A new figure appears here once it is published and verified.
Can I use this data?
Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.
Cite this page
Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Common new active substance approvals across major regulatory authorities (multi-year total) [Data set]. Retrieved September 29, 2026, from https://statorigin.org/indicators/common-new-active-substance-approvals-across-major-regulatory-authorities-multi
"Common new active substance approvals across major regulatory authorities (multi-year total)." StatOrigin, 2026, https://statorigin.org/indicators/common-new-active-substance-approvals-across-major-regulatory-authorities-multi. Accessed 29 Sep. 2026.
StatOrigin. "Common new active substance approvals across major regulatory authorities (multi-year total)." Data set, 2026. Accessed September 29, 2026. https://statorigin.org/indicators/common-new-active-substance-approvals-across-major-regulatory-authorities-multi.
@misc{statorigin_common_new_active_substance_approvals_across_major_regulatory_authorities_multi_2026, title = {Common new active substance approvals across major regulatory authorities (multi-year total)}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/common-new-active-substance-approvals-across-major-regulatory-authorities-multi}, note = {Data set. Accessed 2026-09-29} }